IDEXX Laboratories, Inc. $IDXX Shares Acquired by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 37.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 133,891 shares of the company’s stock after acquiring an additional 36,281 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund’s holdings in IDEXX Laboratories were worth $75,232,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Harbour Investments Inc. lifted its position in shares of IDEXX Laboratories by 13.3% during the 4th quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after buying an additional 16 shares in the last quarter. Rockland Trust Co. increased its holdings in shares of IDEXX Laboratories by 4.4% during the 4th quarter. Rockland Trust Co. now owns 425 shares of the company’s stock worth $288,000 after buying an additional 18 shares during the last quarter. Prime Capital Investment Advisors LLC lifted its position in IDEXX Laboratories by 0.5% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 3,923 shares of the company’s stock valued at $2,654,000 after buying an additional 18 shares during the last quarter. Pinnacle Associates Ltd. boosted its position in shares of IDEXX Laboratories by 1.5% during the 4th quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company’s stock worth $830,000 after purchasing an additional 18 shares during the period. Finally, Triad Wealth Partners LLC increased its stake in IDEXX Laboratories by 3.1% during the first quarter. Triad Wealth Partners LLC now owns 600 shares of the company’s stock worth $337,000 after purchasing an additional 18 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Up 0.9%

Shares of NASDAQ:IDXX opened at $544.32 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The stock has a market cap of $42.94 billion, a P/E ratio of 40.08, a P/E/G ratio of 2.98 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1-year low of $518.55 and a 1-year high of $769.98. The firm has a fifty day moving average price of $556.27 and a 200 day moving average price of $595.41.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period last year, the firm earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on IDXX shares. Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. UBS Group dropped their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Finally, Citigroup assumed coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Six analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.